Ambry Genetics is both CAP-accredited and CLIA-approved. Ambry is able to conduct genetic testing on samples received from any state in the US. In addition, Ambry has special licensure from the states listed below.
|Licensing & Regulatory||Number||Expiration Date|
|CAP Accredited||7154701||October 26, 2016|
|CAP Notice of Ongoing Accreditation|
|CLIA Approved||05D0981414||May 29, 2018|
|State of California||CLF 00011694||April 28, 2017|
|State of Florida||800016789||January 28, 2018|
|State of Maryland||1052||June 30, 2017|
|State of New York||PFI: 8160||December 31, 2016|
|State of Rhode Island||LCO00439||December 30, 2017|
|State of Pennsylvania||027832A||August 15, 2017|
|Notice of Privacy Practices|
|Federalwide Assurance for the Protection of Human Subjects||FWA#: FWA00024430||July 26, 2021|
Ambry Genetics participates in Proficiency Testing provided by the College of American Pathologists (CAP) for all available tests and performs Alternative Proficiency Testing where CAP does not provide an offering. In support of our International clients, Ambry also participates in the United Kingdom National External Quality Assessment Services (UK NEQAS) Molecular Genetics quality assessment schemes. Ambry’s Proficiency Testing program is essential in order to ensure nationally and internationally agreed upon consensus and/or standards in clinical laboratory testing are met.